Products for Research Use Only

Efavirenz-d5

CAT: 0804-HY-10572SSize: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10572SSize:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Efavirenz-d5 (DMP 266-d5) is the deuterium labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[1]. Efavirenz-d5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CAS Number
1132642-95-5
UNSPSC
12352005
Target
Autophagy; HIV; Reverse Transcriptase
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Autophagy
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Solubility
10 mM in DMSO
Smiles
C(#CC1(C(C1([2H])[2H])([2H])[2H])[2H])[C@@]2(C(F)(F)F)C=3C(NC(=O)O2)=CC=C(Cl)C3
Molecular Formula
C14H4D5ClF3NO2
Molecular Weight
320.71
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Young SD, et al. L-743, 726 (DMP-266) : a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39 (12) :2602-5.|[3]Held DM, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281 (35) :25712-22.|[4]Grobler JA, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282 (11) :8005-10.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported